SANTA BARBARA, Calif., July 25, 2013 /PRNewswire/--- VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces today several advancements as it relates to its scientific advancements
Cancer Study Update
Favorable safety data has allowed this study to advance to the fourth and final cohort of phase I. The phase I study has been aimed at examining the safety and efficacy of one of Dr. Karen Newell's Metabolic Disruption Technology compounds, hydroxychloroquine (HCQ), in combination with an existing cancer drug, sorafenib (marketed as Nexavar). This combination treatment has been administered to patients with many different carcinomas. This study is being conducted at the Cancer Therapy & Research Center in San Antonio and the Scott and White Hospital system located in Temple, Texas. "Now that the hurdle of safety is nearly surmounted, we are eager to move into a systematic analysis of the reactions in each group's carcinomas," says Dr. Karen Newell.
American Heart Association Grant
Dr. Karen Roger-Newell and Dr. Brett Mitchell, both professors at Texas A&M, have jointly received a $140,000 grant from the American Heart Association to study the application of the Targeted Peptide Technology (TPT) as it relates to preeclampsia (PE) over a two-year period. "Preliminary data in mice indicate that the treatment not only prevented the development of preeclampsia but also abolished preeclampsia after it had been established as blood pressure and urinary protein levels were normalized within 2-3 days of treatment and there were beneficial effects on fetal development," says Dr. Brett Mitchell. "By targeting specific detrimental immune cells and leaving beneficial protective immune cells alone, the Company's treatment may represent a novel therapy for women with preeclampsia." Specifically, their team will research the role that CLIP+ gamma delta T-cells have in the role in the pathology of PE, and determine the role that these gamma delta T-cells play in blood pressure regulation. Preeclampsia is characterized by the de novo onset of hypertension and proteinuria; it is one of the most common medical disorders during pregnancy, affecting ~8% of all pregnancies world-wide.
Report from UniQuest on VG Energy's LipidMax Technology in Algae
UniQuest Pty. Ltd, the commercialization arm of the University of Queensland, Australia, with a team led by Dr. Ben Hankamer, has completed the final report on VG Energy's LipidMax compound in algae biofuel. The researchers were able to offer additional third party verification that Lipid Max can increase the yield of oil in algae. Further, the researchers were able to show that LM can increase yields in strains resistant to nitrogen depletion as well as in C. protothecoides, a known lipid producing strain. Importantly, the researchers were able to determine that later addition of LM in the algae growth cycle was more effective due to increased algae concentrations.
Ben Hankamer is the director of the Solar Biofuels Consortium, which brings together seven international teams and approximately 100 researchers (www.solarbiofuels.org) working on biofuels and production optimization. The consortium fosters close partnerships with industries that have synergy to establish effective value chains including the biotechnology, engineering, oil, airline and manufacturing industries.
The Hankamer report may be viewed here.
About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, and inflammatory, autoimmune disorders. VGLS controls over 50 US and international patents and pending patents protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.
Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.
Alexandria Sumner, Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
SOURCE VG Life Sciences, Inc.